{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:28Z","timestamp":1790666548247,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105308","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:40:24Z","timestamp":1749141624000},"page":"105308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States"],"prefix":"10.1016","volume":"10","author":[{"given":"R.","family":"Nanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ntalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stwalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sjekloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sadetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105308_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12609-023-00493-3","article-title":"Metastatic triple-negative breast cancer","volume":"15","author":"Zhang","year":"2023","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105308_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105308_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41598-021-04316-2","article-title":"Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105308_bib7","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105308_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105308_bib11","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105308_bib12","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V6.2024. \u00a9National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed December 6, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"6","key":"10.1016\/j.esmoop.2025.105308_bib13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.22.02807","volume":"41","author":"Moy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105308_bib14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105308_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105308_bib16","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105308_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","volume":"31","author":"De","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105308_bib18","first-page":"9","article-title":"Real-world outcomes of sacituzumab govitecan in metastatic breast cancer patients: a single institution experience","volume":"37","author":"Alaklabi","year":"2023","journal-title":"Oncology"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.105308_bib19","article-title":"Abstract P4-07-56: Mayo Clinic enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer","volume":"83","author":"Clark","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105308_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2025.105308_bib21","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020","journal-title":"ArXiv"},{"key":"10.1016\/j.esmoop.2025.105308_bib22","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2023","journal-title":"medRxiv"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105308_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105308_bib24","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2025.105308_bib25","article-title":"Abstract 4089: Time to treatment discontinuation and time to next treatment as proxies of real-world progression-free survival in breast cancer patients","volume":"82","author":"Izano","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105308_bib26","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jval.2020.04.1531","article-title":"PCN25 concordance of real-world time-to-event endpoints with clinical outcomes in oncology studies","volume":"23","author":"Aguilar","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105308_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JOP.18.00750","article-title":"Febrile neutropenia: an ounce of prevention or a pound of cure","volume":"15","author":"Lyman","year":"2019","journal-title":"J Oncol Pract"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105308_bib28","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105308_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2025.105308_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231200454","article-title":"Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany","volume":"15","author":"Reinisch","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105308_bib31","article-title":"Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105308_bib32","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"2014","author":"Mhaskar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105308_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","article-title":"Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): a phase 2 trial","volume":"42","author":"Garc\u00eda","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105308_bib34","doi-asserted-by":"crossref","unstructured":"Lopez-Miranda E, Gion M, Ruiz-Borrego M, et al. Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated w\/sacituzumab govitecan (SG). Paper presented at SABCS, San Antonio, Texas, December 11, 2024. P1-02-06.","DOI":"10.1158\/1557-3265.SABCS24-P1-02-06"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:45:24Z","timestamp":1762598724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925011779"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105308","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105308"}}